Post by ten23 health

🔬 ten23 health is happy to collaborate with dsm-firmenich in the topic of #excipients – read on: 👉🏼 Very few excipients are currently approved for parenteral use in biologics. That constraint is not a minor inconvenience — it limits what formulators can do to address protein aggregation, stability challenges, and degradation in complex therapeutic molecules. It is a problem worth solving. And we are working on it. ten23 health has partnered with dsm-firmenich to evaluate and develop regulatory-ready excipient options for parenteral biologic formulations. dsm-firmenich brings ingredient science expertise and GMP-grade quality documentation; ten23 health contributes its capabilities in biologic formulation development, sterile manufacturing, and advanced analytical testing. The work is still early — but the direction is clear. By generating robust data on how candidate excipients perform in representative protein matrices, the collaboration is building the evidence base needed to responsibly expand what developers can reach for when designing stable, patient-ready biologics. 💉 This is exactly the kind of upstream work that shapes what becomes possible downstream — in development, in manufacturing, and ultimately, for #Patients. If your biologic program is pushing against the limits of what current formulation tools can deliver, this is a conversation worth having. 🔗 Read the full article: https://ow.ly/Napz50ZiCTF #Biologics #FormulationDevelopment #Excipients #ParenteralDrug #SterileInjectables #CDMO #ten23health #BiologicFormulation #DrugDevelopment

Video Content